Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07643428 · ClinicalTrials.gov registry record · Phase 2
Cancer Lipidome Adaptation and Resculping Through Omega-3 PUFAs in Breast Tumors
A Phase 2 study, sponsored by Medical College of Wisconsin.
- Not yet
- Registry status
- Phase 2
- Development phase
- 35
- Enrollment target
NCT07643428: Clinical Trial Phase 2 study, sponsored by Medical College of Wisconsin.
NCT07643428 is a Phase 2 study that has not yet begun recruiting, run by Medical College of Wisconsin. The registered enrollment target is 35 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (74% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07643428, a Phase 2 study, has not yet begun recruiting, sponsored by Medical College of Wisconsin.
- NOT YET RECRUITING
- Registry status
- Phase 2
- Development phase
- 35 participants
- Enrollment target
Study Summary
This is a single-arm Phase 2 interventional treatment study to investigate changes in tissue lipidomes with omega-3 polyunsaturated fatty acids (PUFA) supplementation and correlations with pathological response in patients with early-stage breast cancer. Patients will be treated with a dietary supplement enriched with omega-3 PUFA (O3Supp) for 4 to 28 weeks prior to surgical resection of a breast tumor(s). Concurrent standard-of-care neoadjuvant treatment with clinically indicated systemic agents (such as chemotherapy, endocrine therapy, anti-HER2 therapy, immunotherapy) is allowed.
Primary Outcome
The number of subjects with increased levels of DHA-containing and EPA-containing lipid species in primary breast tumors.
Interventions
- DRUG Mini rTG OMEGA-3 Fish Oil
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2026-09-01 |
| Est. Completion | 2028-06-01 |
| Phase | Phase 2 |
What is known before NCT07643428 opens enrollment
NCT07643428 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 35 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (74% lower).
The record links to 0 conditions, and to 1 intervention - of which Mini rTG OMEGA-3 Fish Oil is the first listed.
NCT07643428 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07643428 about?
NCT07643428 is a clinical study titled "Cancer Lipidome Adaptation and Resculping Through Omega-3 PUFAs in Breast Tumors". This is a single-arm Phase 2 interventional treatment study to investigate changes in tissue lipidomes with omega-3 polyunsaturated fatty acids (PUFA) supplementation and correlations with pathological response in patients with early-stage breast cancer. Patients will be treated with a dietary suppl...
What is the current status of trial NCT07643428?
This trial is currently not yet recruiting. It is a Phase 2 study. The enrollment target is 35 participants. The study started on 2026-09-01. Estimated completion is 2028-06-01.
What interventions are being tested in trial NCT07643428?
The interventions under investigation include: Mini rTG OMEGA-3 Fish Oil (DRUG).
Who is sponsoring clinical trial NCT07643428?
This trial is sponsored by Medical College of Wisconsin, which has 447 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07643428's enrollment target sits among peer trials
35 1524th of 2000 higher than 462 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01697371 · 35 participants · NA
Proton Therapy in the Treatment of Liver Metastases
- NCT01940757 · 35 participants · Phase 1
Experimental Infection of Hookworm-naïve Adults With Dermally-applied Infectious Necator Americanus Hookworm Larvae
- NCT02235857 · 35 participants · NA
Post Approval Study of Liposorber LA-15 System for the Treatment of Focal Segmental Glomerulosclerosis in Children
- NCT02637934 · 35 participants · Phase 1
Phase I Pilot Study of Biodistribution, Metabolism and Excretion of Novel Radiotracer [18F]Fluorthanatrace (FTT) by PET/CT
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI